Amanda Rickard is a research scientist in the Epigenetics group at Pfizer Oncology in San Diego. She previously led the FSHD therapeutics discovery team at Genea Biocells where she used pluripotent stem cells to model FSHD muscle debilitation. Her team discovered GBC0905, DUX4-silencing small molecule, which was granted FDA Orphan Drug Designation for the treatment of FSHD in 2018. Previous to that she worked for Dr. Dan Miller at the University of Washington's Institute for Stem Cell and Regenerative Medicine studying the molecular mechanisms of FSHD. Amanda is also a member of our Scientific Advisory Board.